Trial Profile
ANTI-MULLERIAN HORMONE (AMH) AS A MARKER OF OVARIAN RESERVE IN YOUNG BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY + GnRH ANALOGUE
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Jul 2014
Price :
$35
*
At a glance
- Drugs Triptorelin (Primary)
- Indications Breast cancer
- Focus Biomarker; Therapeutic Use
- 09 Jul 2014 New trial record